Mazonakis died on 9 September after suffering a heart attack while undergoing plasmapheresis.

Researchers identified PLA2G2F, an enzyme whose expression increases with age and appears to help protect the brain against age-related changes.

Boosting its activity in older mice preserved spatial memory, reduced synaptic loss and limited inflammation-related changes. Human brain samples also linked higher expression to cognitive resilience despite Alzheimer's pathology.

The findings are preclinical. Whether targeting this enzyme could help humans remains unknown.

Paper on a method to restore enamel to teeth. Some of the research was done on teeth extracted from donors.

Part of the abstract below:

Regrowth of lost enamel in tooth decay and sensitivity is a major obstacle to overcome. Here, the authors report on a protein-based material that mimics features of natural enamel formation, allowing for epitaxial growth of apatite nanocrystals to restore enamel structure and function.

BIOGAMI teams will decode the “grammar” that guides how intrinsically disordered proteins (IDPs) behave and create new ways to steer misfolded or clumped (aggregated) proteins back into healthy shapes. The program focuses on the very earliest steps in the misfolding process — before proteins clump together and damage cells — especially in the brain and other vulnerable tissues. By acting early, BIOGAMI aims to stop neurodegenerative disease and other chronic diseases before they fully develop, instead of only treating symptoms after serious damage has occurred. 

ARDD 2026 recordings are being uploaded to their YouTube channel (https://www.youtube.com/@ardd3628/videos). Feel free to post individual videos you find interesting, but try to avoid reposts.

Finding and testing new longevity medicines, with updates on research, pharma involvement, biomarkers for human trials and the limits of AI.

The peer-reviewed study identified SRSF1 through a transcriptomic screening platform; the lifespan experiment was small, with 9–10 mice per group, so the result is promising but still early.

A string of longevity meetings (ARDD, Biomarkers of Aging, etc.) just wrapped up in Boston and I have to assume some folks here showed up. Please share any highlights!